BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company dedicated to developing novel antibacterial treatments for life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The event, scheduled for September 14-16, 2026, in New York City, provides a platform for the company to present its strategic vision and recent pipeline advancements to the investment community.
During the conference, BioVersys' Chief Financial Officer, Hernan Levett, will deliver a corporate overview on September 16, 2026, from 12:30 to 1:00 PM ET at the Kennedy II room of the Lotte New York Palace. Additionally, a pre-recorded presentation by Chief Executive Officer, Dr. Marc Gitzinger, will be available on demand starting September 11, 2026, at 7:00 AM ET, with a 90-day replay period. The webcast can be accessed via the H.C. Wainwright platform or through the investor section of the BioVersys website. The company's leadership will also engage in one-on-one meetings with registered attendees, facilitated by H.C. Wainwright representatives.
This presentation comes at a critical juncture for BioVersys, which is advancing a robust pipeline targeting some of the most challenging pathogens. The lead program, BV100, is in Phase 3 development for nosocomial infections caused by Acinetobacter baumannii, a bacterium classified by the World Health Organization as a priority pathogen due to its resistance to multiple antibiotics. Additionally, the company is developing alpibectir for tuberculosis, currently in Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France. These programs underscore the company's commitment to addressing the rising global threat of antimicrobial resistance (AMR), which the World Health Organization has identified as one of the top ten global public health threats.
The significance of BioVersys' work is amplified by the dwindling pipeline of new antibiotics. In recent decades, the discovery of novel classes of antibiotics has slowed dramatically, while resistance has spread, leading to an estimated 1.27 million deaths directly attributable to AMR annually. BioVersys leverages two proprietary technology platforms, TRIC and Ansamycin Chemistry, to design candidates that can overcome resistance mechanisms, block virulence production, and directly target pathogenic bacteria. This approach not only aims to treat acute infections but also to address chronic inflammatory conditions exacerbated by bacteria, such as those affecting the microbiome.
Investor interest in BioVersys is likely heightened by its strategic partnerships and the potential for significant clinical milestones. The collaboration with GSK for alpibectir brings substantial resources and expertise, while the Phase 3 trial for BV100 could position the company for regulatory submission in a high-need area. The presentation at the H.C. Wainwright conference offers an opportunity for BioVersys to articulate its value proposition to potential investors and partners, emphasizing the commercial potential of its pipeline and the societal impact of combating AMR.
As BioVersys continues to advance its candidates, the outcomes of these trials will be closely watched by the medical and investment communities. The conference participation is a key step in raising awareness and securing the necessary capital to bring these much-needed therapies to patients. With the World Health Organization calling for global action on AMR, BioVersys' work is not only a commercial endeavor but also a critical public health initiative.
